Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
27 hedge funds and large institutions have $5.53M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
10% less funds holding
Funds holding: 30 → 27 (-3)
23% less capital invested
Capital invested by funds: $7.15M → $5.53M (-$1.62M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$179K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.3K |
| 3 |
TI
Telemetry Investments
New York
|
+$64.4K |
| 4 |
Two Sigma Advisers
New York
|
+$62.8K |
| 5 |
Two Sigma Investments
New York
|
+$47.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSWM
Smith Salley Wealth Management
Greensboro,
North Carolina
|
-$241K |
| 2 |
Renaissance Technologies
New York
|
-$102K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$56.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$30K |
| 5 |
Millennium Management
New York
|
-$17K |
FRTX Hedge Fund Activity: Q3 2021 in Review
27 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2021, worth a combined $5.53M — down 23% from $7.15M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FRTX and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $179K. The largest seller was Smith Salley Wealth Management, cutting an estimated $241K.
- 27 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2021, down from 30 in Q2 2021.
- Funds reported $5.53M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2021, down 23% quarter-over-quarter.
- 2 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2021 and 4 closed out, a net change of -2 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2021 was GSA Capital Partners, an estimated $179K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2021 was Smith Salley Wealth Management, an estimated $241K sold.
Based on aggregated 13F filings for Q3 2021.